Profitability Ratios
| Ratio |
Value |
| GP Margin |
56.6% |
| EBIT Margin |
-8.2% |
| EBITDA Margin |
-3.2% |
| Operating Margin |
-9.8% |
| Pretax Margin |
-8.2% |
| Cont. Ops Margin |
-8.8% |
| Net Margin |
-9.6% |
| Bottom Line Margin |
-9.6% |
Liquidity Ratios
| Ratio |
Value |
| Current Ratio |
4.72 |
| Quick Ratio |
3.86 |
| Solvency Ratio |
-0.110 |
| Cash Ratio |
2.62 |
Valuation Ratios
| Ratio |
Value |
| Price/Earnings |
|
| PEG Ratio |
0.16 |
| Forward PEG |
0.16 |
| Price/Book |
0.96 |
| Price/Sales |
1.22 |
| Price/FCF |
31.59 |
| Price/Op Cash Flow |
12.32 |
Debt Ratios
| Ratio |
Value |
| Debt/Assets |
0.1380 |
| Debt/Equity |
0.1830 |
| Debt/Capital |
0.1547 |
| Long-Term Debt/Capital |
0.1443 |
| Financial Leverage |
1.33 |
Cash Flow Ratios
| Ratio |
Value |
| Working Capital Turnover |
1.31 |
| Operating Cash Flow Ratio |
0.511 |
| Operating Cash Flow/Sales |
9.9% |
| Free Cash Flow/Operating Cash Flow |
39.0% |
Coverage Ratios
| Ratio |
Value |
| Debt Service Coverage |
0.00 |
| Interest Coverage |
0.0000 |
| Short-Term Operating Cash Flow Coverage |
0.00 |
| Operating Cash Flow Coverage |
0.43 |
| Capital Expenditure Coverage |
1.64 |
| Dividend + Capital Expenditure Coverage |
1.64 |
Dividend Ratios
| Ratio |
Value |
| Payout Ratio |
0.0000% |
| Dividend Yield |
0.0000% |
| Dividend Yield % |
0.0000% |
| Dividend Per Share |
0.0000 |
Per Share Ratios
| Ratio |
Value |
| Revenue/Share |
7.87 |
| EPS |
-0.759 |
| Debt/Share |
1.8305 |
| Cash/Share |
4.01 |
| Book Value/Share |
10.01 |
| Tangible BV/Share |
9.33 |
| Equity/Share |
10.01 |
| Operating Cash Flow/Share |
0.780 |
| Capital Expenditure/Share |
0.476 |
| FCF/Share |
0.304 |
Other Ratios
| Ratio |
Value |
| Net Income/Earnings Before Tax |
1.169 |
| Earnings Before Tax/EBIT |
0.842 |
| Price/Fair Value |
0.96 |
| Debt/Market Cap |
0.1756 |
| Effective Tax Rate |
-7.2% |
| Enterprise Value Multiple |
-29.78 |
ANIK - Anika Therapeutics, Inc.